Introduction {#sec1}
============

The naturally occurring spirooxindoles possessing diverse biological activities have been attracting great interest among chemists for decades, and considerable efforts have been devoted to the synthesis of the spirooxindole motif ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref1]^ Extensive approaches have been produced toward the synthesis of spirooxindole scaffolds from isatins.^[@ref2]^ More recently, asymmetric catalysis strategies^[@ref3]^ and organocatalytic cascade approaches^[@ref4]^ were applied in these syntheses. In addition, inspired by the natural-product-derived spirooxindoles, new therapeutic agents have been discovered from a variety of derivatives^[@ref5]^ and have led to some clinical trials or preclinical studies, e.g., CFI-400945,^[@ref6]^ MI-77301(SAR-405838), and MK-0677. Moreover, among the spirooxindole syntheses, the preparation of chiral spirooxindole scaffolds with a five-membered ring is of great interest to synthetic chemists. Nevertheless, facile construction of such systems bearing multiconsecutive stereocenters and multiquaternary stereocenters have been less reported and the approaches have been usually limited to those reactions wherein methyleneindolinones serve as dipolarophiles and Michael acceptors.^[@ref7]^ In this context, the development of efficient methods for the asymmetric synthesis of spirooxindole with multiconsecutive stereocenters and functionalities continues to be a great need in the search for new lead compounds in drug discovery.

![Examples of naturally occurring and synthetic bioactive spirooxindoles.](ao-2018-03049j_0008){#fig1}

Because of their ability to efficiently construct multi-stereocenters and multibonds in a single operation, organocatalytic domino or cascade reactions have constituted an important tool in contemporary synthetic chemistry.^[@ref8]^ Since the turn of this century, various organocatalysts and substrates with exquisitely designed functionalities have been introduced and employed in a variety of reactions. Among them, the Michael reaction has been demonstrated to be one of the most practical and successful reactions.^[@ref9]^

The organocatalyzed cascade conjugate additions (Michael reaction) of nitroalkane (without the α-carbonyl activating group) to nitroalkene have been realized recently^[@ref10]^ compared with the well-studied reactions of aldehydes to nitroalkenes and the reactions of nitroalkanes to enals. Additionally, bifunctional squaramide organocatalysts^[@ref11]^ have been recently developed after the proliferation of amine-based and thiourea-based organocatalysts and have proven to be efficacious promoters for asymmetric catalysis. Despite the advances of these catalysts in contemporary asymmetric synthesis, the diverse applications of the domino catalytic reactions in the synthesis of multi-stereocenters and multiring systems remain a highly compelling line of investigation.

Inspired by the aforementioned background and the continuing efforts in elucidating the organocatalytic domino reactions,^[@ref12]^ we envisioned that the asymmetric synthesis of the chiral spirooxindole motif could be achieved by the reaction of a rationally designed 3-(3-nitroallyl)indolin-2-one (**1a**) and a nitroolefin bearing an electron-withdrawing moiety in the α-position ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). However, the following obstacles impede these domino reactions: (1) the conceivable self-alkylation of nitrooxindole **1** through nitro-Michael additions;^[@ref13]^ (2) efficient activation of the nitroalkene **2** as a Michael acceptor, generating the nitroalkane, and the subsequent alkylation to the nitroalkene moiety on **1**; and (3) the need to control stereoselectivity in the construction of a sterically hindered spirooxindole with four contiguous stereocenters, including two quaternary centers. As such, bifunctional catalysts may be able to overcome these impediments.

![Retrosynthetic Analysis](ao-2018-03049j_0002){#sch1}

Results and Discussion {#sec2}
======================

At the beginning, the reactions of nitrooxindole **1a** and nitroalkene ester (*Z*)-**2a** were studied with different organocatalysts in CH~2~Cl~2~ at room temperature and at a concentration of 0.3 M ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The reactions catalyzed with pyrrolidine (**I**) provided tiny amount of the product after 2 days, with recovery of the starting **1a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). The reaction with triethylamine as the catalyst gave a 41% yield of the products, which was useful as a racemic standard in the next-stage high-performance liquid chromatography (HPLC) analysis. The Takemoto catalyst (**II**)-catalyzed reaction of **1a** with **2a** afforded the spirooxindoles **3a** and **4a** in 63% yield with a ratio of 61:39 and 64% ee of the major product **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 3). The reaction with squaramide **III** gave a 66% yield of the spirooxindoles **3a** and **4a** and 96% ee of the opposite enantiomers **3a** obtained above ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 4). Promisingly, the reaction catalyzed by squaramide **IV** provided 70% yield of the anticipated adducts **3a** and **4a** in a ca. 81:19 ratio and 94% ee of the major product **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 5). The process with catalyst **V** did not improve dr or ee, whereas the reaction with catalyst **VI** afforded 85% ee of **3a** and with a lesser yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 6 and 7). Later, examination of the reaction with catalyst **IV** in different solvent media, e.g., dichloroethane, toluene, tetrahydrofuran (THF), and CH~3~CN, identified that CH~3~CN was the optimal medium for the process, in terms of yields (70%) and diastereoselectivity of **3a** and **4a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--11). In addition, the reaction afforded a ratio of 91:9, favoring the major product **3a** in 94% ee, albeit lower ee (55% ee) was observed in the minor product **4a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 11). On the other hand, the reaction catalyzed by **VII** in CH~3~CN gave similar yields to those from the reaction catalyzed by **IV**, but with slightly lower dr and ee ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 12). Raising the reaction temperature with catalyst **IV** in CH~3~CN to 60 °C facilitated the reaction to achieve completion in 13 h, compared to 24 h at room temperature, yet a lower ee of **3a** was observed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 13). Based on these findings, in consideration of yields, diastereoselectivity, and enantioselectivity, the condition shown in entry 11 was selected for the subsequent study.

###### Optimization of the Domino Reaction Conditions[a](#t1fn1){ref-type="table-fn"}^,^[b](#t1fn2){ref-type="table-fn"}

![](ao-2018-03049j_0005){#fx1}

  entry                                catalyst   solvent      time   yield   dr[c](#t1fn3){ref-type="table-fn"}   ee[d](#t1fn4){ref-type="table-fn"}^,^[e](#t1fn5){ref-type="table-fn"}
  ------------------------------------ ---------- ------------ ------ ------- ------------------------------------ -----------------------------------------------------------------------
  1                                    **I**      CH~2~Cl~2~   48     5       nd                                   0
  2                                    TEA        CH~2~Cl~2~   10     41      68:32                                0
  3                                    **II**     CH~2~Cl~2~   30     63      61:39                                64
  4                                    **III**    CH~2~Cl~2~   36     66      76:24                                --96 (−59)
  5                                    **IV**     CH~2~Cl~2~   40     70      81:19                                94
  6                                    **V**      CH~2~Cl~2~   48     68      70:30                                85
  7                                    **VI**     CH~2~Cl~2~   40     62      73:27                                85 (40)
  8                                    **IV**     DCE          23     70      70:30                                nd
  9                                    **IV**     toluene      40     55      91:9                                 nd
  10                                   **IV**     THF          24     68      88:12                                nd
  11                                   **IV**     CH~3~CN      24     70      91:9                                 94 (55)
  12                                   **VII**    CH~3~CN      24     72      85:15                                92 (51)
  13[f](#t1fn6){ref-type="table-fn"}   **IV**     CH~3~CN      13     68      86:14                                82 (50)

The reactions were carried out on a 0.3 M scale of **1a** (1.0 equiv) and **2a** (1.5 equiv) with catalyst (20 mol %) at room temperature (∼30 °C).

Yields of **3a** and **4a** isolated.

Determined by crude ^1^H NMR.

The values of ee were measured by HPLC analysis with a chiral column (Chiralpak IC).

The ee of minor product **4a** in parenthesis.

The reaction was performed at 60 °C. nd = not determined.

Accordingly, we explored the cascade reactions in regard to nitrooxindole **1** and nitroalkene ester **2** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The results were encouraging, and promising outcomes were observed with respect to the derivatives tested, providing the products in good yields (64--73%) with persistently good enantioselectivities (92--97%) of major product **3**. The reactions usually required roughly a day for completion. In addition, the reactions provided adducts **3** and **4** in a ratio of around 80:20 or higher, whereas the dr was increased to ca. 90:10 in some reactions ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, entries 1 and 3). The structure of seven products in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} was explicitly confirmed by X-ray crystallography analysis. The stereo plots of the X-ray crystal analyses of (±)-**3b**, (±)-**4b**, and (+)-**3j** are shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![Stereo plots of the X-ray crystallographic analyses of (±)-**3b**, (±)-**4b**, (+)-**3j**, (+)-**7a**, (±)-**8a**, (+)-**9b**, and (±)-**8b**; C, gray; O, red; N, blue; Br: purple.](ao-2018-03049j_0007){#fig2}

###### Examples of the Domino Michael--Michael Reaction[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-03049j_0006){#fx2}

  entry   product                         *t* (h)   yield (%)[b](#t2fn2){ref-type="table-fn"}   dr (%)[c](#t2fn3){ref-type="table-fn"}**3**/**4**   ee (%)[d](#t2fn4){ref-type="table-fn"}**3**/**4**
  ------- ------------------------------- --------- ------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  1       **a**. R~1~ = H, R~2~ = H       24        70                                          91:9                                                94:55
  2       **b**. R~1~ = H, R~2~ = Me      24        73                                          84:16                                               95:58
  3       **c**. R~1~ = Me, R~2~ = Me     29        68                                          90:10                                               95:68
  4       **d**. R~1~ = H, R~2~ = Br      24        66                                          83:17                                               97:65
  5       **e**. R~1~ = Me, R~2~ = Br     28        65                                          83:17                                               97:44
  6       **f**. R~1~ = H, R~2~ = F       23        67                                          83:17                                               94:67
  7       **g**. R~1~ = Me, R~2~ = F      26        65                                          78:22                                               95:23
  8       **h**. R~1~ = H, R~2~ = NO~2~   29        70                                          70:30                                               92:46
  9       **i**. R~1~ = H, R~2~ = Et      32        73                                          82:18                                               94:69[e](#t2fn5){ref-type="table-fn"}
  10      **j**. R~1~ = Me, R~2~ = H      27        66                                          84:16                                               97:42

The reactions were carried out on a 0.3 M scale of **1** (1.0 equiv) and **2** (1.5 equiv) in CH~3~CN at room temperature (∼30 °C).

Yields of **3** and **4** isolated.

Analyzed by ^1^H NMR of the crude reaction mixture.

The ee was determined by HPLC analysis with column Chiralpak IC.

The ee was determined with column Chiralpak IA.

Additionally, the reaction of **2a** (*E*/*Z* mixture in a ratio of 2.2:1) and **1a** under the same reaction conditions (0.2 equiv of catalyst **IV** in CH~3~CN) for 24 h gave 66% yield of products **3a** and **4a**, with relatively similar dr (78:22) and enantioselectivities (92 and 61% ee, respectively) to those obtained from the reaction with (*Z*)-**2a**. This observation implies that the stereoselective domino reactions are irrelevant to the stereochemistry of the starting nitroolefin esters, e.g., **2a**.

To elucidate the result of this cascade process, a plausible mechanism is presented in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. The original Michael reaction of **1a** to nitroalkene ester **2a** via the squaramide hydrogen-bonding activation process (transition state **TS A**) could engender intermediate **C**, followed by the Michael reaction of squaramide-amine-activated nitroester to nitroolefin, providing the adduct **3a**. On the other hand, the Michael reaction of **1a** to nitroalkene **2a** through **TS B**, which is less favorable than **TS A** owing to steric effect, could provide intermediate **D**. Succeeding Michael addition affords the spirooxindole adduct **4a** as the minor product. The development of **3a** and **4a** is conceivably controlled by a dynamic equilibrium progression wherein elegant arrangement is crucial and only stable transition states or intermediates are obtainable.^[@ref14]^

![Proposed Reaction Mechanism](ao-2018-03049j_0003){#sch2}

Quite a few amino esters, e.g., valaciclovir and SNX-5422, have been approved as medical drugs or used in clinical trials. Therefore, preparation of the spirooxindole with α-amino esters would be of interest. Accordingly, a sequential double Michael-reduction process was conducted with the reaction of **1a** and (*Z*)-**2a**, followed by the hydrogenation on Pd/C in MeOH to give the amino ester **5a** and **6a** in 48% yields, without isolation of the first-step products (**3a** and **4a**), [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}a. In addition, the reaction with *meta*-bromo nitrostyrene gave a lesser yield of **3k** and **4k**, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}b. On the other hand, the reactions of **1b** with a nitrostyrene lacking the α-ester group, i.e., nitrostyrene and 4-bromo-β-nitrostyrene, are problematic, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}c--e. For example, the reaction of **1b** and nitrostyrene with catalyst **IV** in CH~2~Cl~2~ required a longer time than that required for the reaction with α-ester nitrostyrene (*Z*)-**2a** (46 h vs ca. 24 h) and gave only 45% yield of products **7a** and **8a** (as the major products in a 81:19 ratio and much lower ee), along with many other complicated mixtures, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}c. In addition, the same reaction with 4-bromo-β-nitrostyrene afforded 49% yield of the products **9b** and **8b** (as the major products in a 72:28 ratio and low ee too), [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}d. However, in this reaction with 4-bromo-β-nitrostyrene, a different isomeric product **9b** with **7a**, arising from the epimerization of the CHNO~2~ group, was isolated as the major product. This reaction has been repeated twice, and the same results were obtained. Exact reasons causing this disparity are unknown but may be the stronger acidity of the methine on CHNO~2~ and the steric congestion of the bromo-substituted compound. In comparison, the same reaction with the catalyst **III** gave similar yields and ratios of the products **9b** and **8b** to those from transformation with catalyst **IV**, but with opposite enantioselectivity and better ee of the major product **9b**, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}e. The structures of the X-ray crystallography analysis of (+)-**7a**, (±)-**8a**, (+)-**9b**, and (±)-**8b** are elucidated in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. In short, these results highlight the merit of introducing the α-substituted ester group on the nitroolefin to increase the yields and stereoselectivity in these reactions.

![Synthesis of the Other Derivatives and the Related Experiments](ao-2018-03049j_0004){#sch3}

Conclusions {#sec3}
===========

In summary, we have established a squaramide-amine catalyzed domino Michael--Michael reaction for the construction of spirooxindoles with four adjacent stereocenters, including a quaternary α-nitro ester with high enantioselectivity. The transformation of the product to the α-amino esters was demonstrated. The process not only furnished a succinct manner for the construction of cyclopentane-fused spirooxindoles but also increased the reaction feasibility and stereoselectivity by introducing appropriate α-substituents on the nitroolefin and suitable squramide-amine bifunctional catalysts that would provide otherwise unattainable products and stereoselectivities. The structures of 11 products were explicitly determined by single-crystal X-ray diffraction analysis.^[@ref16]^ Given the considerable importance of spirooxindoles in chemistry and medical studies, the domino reaction protocol could contribute a useful implement to asymmetric synthesis. Further elaboration of the synthetic method in other specific examples is now in progress.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All chemicals and solvents were purchased as reagent grade from commercial suppliers. Catalyst **II** (CAS no: 620960-26-1) was purchased from Strem Chemicals; catalyst **V** (CAS no: 1211565-07-9), catalyst **III** (CAS no: 1256245-84-7), and catalyst **VII** (1211565-11-5) were purchased from Daicel Chiral Technologies. In addition, catalysts **III** and **VI** were also prepared according to the literature procedure.^[@ref15]^ Catalyst **IV** (CAS no: 1211565-08-0) was purchased from Sigma-Aldrich and Daicel Chiral Technologies. Catalyst **VI** was prepared from (+)-quinidine (CAS number 56-54-2, purchased from Alfa Aesar).^[@cit15a],[@ref16]^ Reactions were usually proceeded under a nitrogen atmosphere in vials or pear-shaped flasks. Flash column chromatography was carried out with Merck silica gel 60 (particle size 0.04--0.063 mm). Melting points were reported uncorrected and were recorded on an automated melting point apparatus (Stanford Research System MPA-100). ^1^H NMR spectra were recorded at 500 MHz (Varian-Unity INOVA-500) or 400 MHz (Bruker AscendTM 400 or Bruker DPX-400), respectively, and ^13^C NMR spectra were recorded at 125 or 100 MHz. The enantiomeric excess (ee) values were determined by HPLC on a Hitachi HPLC system (Hitachi pump L-2130 and Hitach diode array detector L-2455) with a chiral column (chiralpak IA or IC, 0.46 cm ID x 25 cm, particle size 5 μ) using a mobile phase containing THF--hexane or *i*-PrOH--hexane. The optical rotation values were measured with a Jasco P-2000 polarimeter.

General Procedure for the Synthesis of (*Z*)-Nitroolefin {#sec4.2}
--------------------------------------------------------

To a solution of benzaldehyde (1 g, 9.42 mmol, 1 equiv) and anhydrous magnesium sulfate (340 mg, 2.8 mmol, 0.3 equiv) in dry THF (3 mL) was added aniline (877 mg, 9.42 mmol, 1 equiv) at room temperature (∼30 °C). The resulting solution was stirred at ambient temperature for 5 h, followed by dilution with CH~2~Cl~2~ (10 mL). The solution was filtered and concentrated in vacuo to give an oil residue. The crude imine product (1.69 g) was used for the next-step reaction without further purification. A solution of ethyl nitroacetate (1 mL, 9.01 mmol) in acetic anhydride (10 mL) was heated to 50 °C. To this preheated solution was added the above prepared crude imine product (1.69 g) and rinsed with Ac~2~O (2 mL), and the resulting solution was stirred at 50 °C for 14 h until the completion of the reaction. The reaction was quenched by the addition of water (10 mL), and the reaction mixture was extracted with CH~2~Cl~2~ (100 mL × 3). The organic solution was washed with brine (50 mL × 3), dried over MgSO~4~, and concentrated in vacuo to give a crude residue. The crude product was purified by flash column chromatography with 10% EtOAc--hexane (*R*~*f*~ = 0.47 in 20% EtOAc--hexane) to afford **2a** (1.83 g, 88% yield, *Z*/*E* = 2.3:1 analyzed by ^1^H NMR). The pure (*Z*)-**2a** was obtained upon recrystallization in hexane--CH~2~Cl~2~ (15:3 mL).

### (*Z*)-Ethyl 2-Nitro-3-phenylacrylate (*Z*-**2a**) {#sec4.2.1}

Mp: 72--73 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 7.52 (s, 1H), 7.48--7.43 (m, 1H), 7.42--7.38 (m, 4H), 4.36 (q, *J* = 7.0 Hz, 2H), 1.35 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 159.43 (C), 140.49 (C), 133.12 (CH), 132.36 (CH), 129.94 (two CH), 129.59 (two CH), 129.19 (C), 63.30 (CH~2~), 14.26 (CH~3~);^[@ref17]^ MS (*m*/*z*, relative intensity): 221 (M^+^, 6), 205 (4), 193 (17), 176 (9), 147 (15), 132 (37), 129 (24), 103 (47), 102 (100), 91 (63), 77 (64); exact mass calculated for C~11~H~11~NO~4~ (M^+^): 221.0688; found: 221.0685.

### (*Z*)-Ethyl 2-Nitro-3-(*p*-tolyl)acrylate (*Z*-**2b**) {#sec4.2.2}

White solid. Mp 66--67 °C. Yield: 1.79 g (91%, *Z*/*E* = 2.1:1). Column chromatography eluents: 10% EtOAc--hexane (thin layer chromatography (TLC): *R*~*f*~ = 0.60); ^1^H NMR (500 MHz, CDCl~3~): δ 7.48 (s, 1H), 7.30 (d, *J* = 8 Hz, 2H) 7.20 (d, *J* = 8 Hz, 2H), 4.35 (q, *J* = 7.0 Hz, 2H), 2.37 (s, 3H), 1.34 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 159.62 (C), 143.45 (C), 139.66 (C), 133.18 (CH), 130.36 (two CH), 130.12 (two CH), 126.37 (C), 63.16 (CH~2~), 21.85 (CH~3~), 14.28 (CH~3~);^[@cit17a]^ MS (*m*/*z*, relative intensity): 236 (M^+^ + 1, 5), 235 (M^+^, 55), 207 (9), 190 (11), 162 (16), 161 (24), 146 (34), 143 (22), 120 (32), 119 (51), 116 (75), 115 (100), 105 (32), 91 (54); exact mass calculated for C~12~H~13~NO~4~ (M^+^): 235.0845; found: 235.0834.

### (*Z*)-Ethyl 3-(4-Bromophenyl)-2-nitroacrylate (*Z*-**2c**) {#sec4.2.3}

White solid. Mp 72--73 °C. 1.39 g, yield: (86%, *Z*/*E* = 1.8:1). Column chromatography eluents: 20% EtOAc--hexane (TLC: *R*~*f*~ = 0.53); ^1^H NMR (500 MHz, CDCl~3~): δ 7.53 (d, *J* = 8.5 Hz, 2H), 7.44 (s, 1H), 7.25 (d, *J* = 8.5 Hz, 2H), 4.36 (q, *J* = 7.0 Hz, 2H), 1.34 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 159.18 (C), 140.78 (C), 132.95 (two CH), 131.80 (CH), 131.19 (two CH), 128.02 (C), 127.20 (C), 63.45 (CH~2~), 14.23 (CH~3~);^[@cit17a]^ MS (*m*/*z*, relative intensity): 301 (M^+^ + 2, 16), 299 (M^+^, 17), 227 (19), 225 (20), 212 (19), 210 (25), 209 (18), 207 (17), 185 (33), 183 (43), 182 (100), 180 (95), 148 (24), 101 (95), 89 (67), 75 (67); exact mass calculated for C~11~H~10~BrNO~4~ (M^+^): 298.9793; found: 298.9791.

### (*Z*)-Ethyl 3-(4-Fluorophenyl)-2-nitroacrylate (*Z*-**2d**) {#sec4.2.4}

White solid. Mp 52--53 °C. 1.74 g, yield: (90%, *Z*/*E* = 2:1). Column chromatography eluents: 20% EtOAc--hexane (TLC: *R*~*f*~ = 0.52); ^1^H NMR (500 MHz, CDCl~3~): δ 7.47 (s, 1H), 7.44--7.39 (m, 2H), 7.13--7.07 (m, 2H), 4.36 (q, *J* = 7.0 Hz, 2H), 1.35 (t, *J* = 7.0 Hz, 3H);^[@ref18]13^C NMR (100 MHz, CDCl~3~): δ 164.99 (d, *J* = 254 Hz, C), 159.34 (C), 140.23 (C), 132.35 (d, *J* = 9 Hz, two CH), 131.82 (CH), 125.43 (d, *J* = 3 Hz, C), 117.02 (d, *J* = 22 Hz, two CH), 63.37 (CH~2~), 14.26 (CH~3~); MS (*m*/*z*, relative intensity): 240 (M^+^ + 1, 5), 239 (M^+^, 40), 193 (12), 165 (25), 150 (22), 147 (21), 123 (31), 120 (100), 109 (20), 101 (20); exact mass calculated for C~11~H~10~FNO~4~ (M^+^): 239.0594; found: 239.0591.

### (*Z*)-Ethyl 2-Nitro-3-(4-nitrophenyl)acrylate (*Z*-**2e**) {#sec4.2.5}

White solid. Mp 107--108 °C. 1.47 g, yield: (83% yield, *Z*/*E* = 1.9:1). Column chromatography eluents: 20% EtOAc--hexane (TLC: *R*~*f*~ = 0.50); ^1^H NMR (500 MHz, CDCl~3~): δ 8.25 (d, *J* = 8.5 Hz, 2H), 7.58 (s, 1H), 7.57 (d, *J* = 8.5 Hz, 2H), 4.40 (q, *J* = 7.0 Hz, 2H), 1.36 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 158.60 (C), 149.49 (C), 142.89 (C), 135.21 (C), 130.44 (two CH), 130.35 (CH), 124.63 (two CH), 63.91 (CH~2~), 14.21 (CH~3~);^[@cit17b]^ MS (*m*/*z*, relative intensity): 267 (M^+^ + 1, 5), 266 (M^+^, 38), 221 (48), 219 (37), 192 (78), 190 (50), 177 (51), 175 (40), 174 (35), 162 (34), 149 (37), 148 (51), 147 (100), 118 (33), 101 (94), 89 (61), 75 (65); exact mass calculated for C~11~H~10~N~2~O~6~ (M^+^): 266.0539; found: 266.0536.

### (*Z*)-Ethyl 3-(4-Ethylphenyl)-2-nitroacrylate (*Z*-**2f**) {#sec4.2.6}

White solid. Mp 53--54 °C. 1.537 g, yield: (83% yield, *Z*/*E* = 1.7:1). Column chromatography eluents: 20% EtOAc--hexane (TLC: *R*~*f*~ = 0.60); IR (neat): 2970, 2936, 1725, 1642, 1608, 1537, 1382, 1370, 1269, 1205, 1185, 1072, 829 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.48 (s, 1H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.21 (d, *J* = 8.5 Hz, 2H), 4.34 (q, *J* = 7.0 Hz, 2H), 2.64 (q, *J* = 7.5 Hz, 2H), 1.33 (t, *J* = 7.0 Hz, 3H), 1.2 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 159.51 (C), 149.51 (C), 139.58 (C), 133.03 (CH), 130.15 (two CH), 129.08 (two CH), 126.47 (C), 63.05 (CH~2~), 29.00 (CH~2~), 15.11 (CH~3~), 14.16 (CH~3~); MS (*m*/*z*, relative intensity): 250 (M^+^ + 1, 8), 249 (M^+^, 57), 204 (11), 175 (31), 160 (38), 148 (31), 131 (46), 130 (61), 115 (100), 103 (39), 91 (41), 77 (31); exact mass calculated for C~13~H~15~NO~4~ (M^+^): 249.1001; found: 249.1002.

General Procedure for the Synthesis of Products **3a** and **4a** {#sec4.3}
-----------------------------------------------------------------

To a solution of catalyst **IV** (9.7 mg, 0.02 mmol, 0.2 equiv) and **1a** (25 mg, 0.11 mmol, 1 equiv)^[@cit12b]^ in CH~3~CN (0.4 mL) was added (*Z*)-**2a** (38 mg, 0.17 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 24 h until the completion of the reaction, as monitored by TLC. The resulting mixture was diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL), dried over MgSO~4~, and concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 91:9. The residue was purified by flash column chromatography with 20% EtOAc--hexane (*R*~*f*~ = 0.37 for **3a**, *R*~*f*~ = 0.50 for **4a** in 40% EtOAc--hexane) to give products **3a** and **4a** (35 mg, 70% yield). Chiral HPLC analysis for **3a**: Chiralpak IC (elute: 20% isopropanol (IPA)--hexane), flow rate 1.0 mL/min, detector: 225 nm, *t*~1~ = 7.23 min, *t*~2~ = 8.77 min, 3:97 er. Chiral HPLC analysis for **4a**: Chiralpak IC (elute: 20% IPA--hexane), flow rate 1.0 mL/min, detector: 280 nm, *t*~1~ = 6.78 min, *t*~2~ = 16.96 min, 77.4:22.6 er.

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3a**) {#sec4.3.1}

White solid, mp: 154--155 °C; \[α\]~D~^26^ 18.1 (*c* 1, CHCl~3~); IR (neat): 3374, 3252, 2925, 2855, 1749, 1708, 1620, 1557, 1472, 1374, 1344, 1251, 758, 702 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.84 (d, *J* = 7.5 Hz, 1H), 7.72 (s, 1H), 7.26--7.19 (m, 1H), 7.17--7.07 (m, 2H), 7.02 (t, *J* = 7.5 Hz, 2H), 6.88 (d, *J* = 7.5 Hz, 2H), 6.75 (d, *J* = 7.5 Hz, 1H), 5.43 (s, 1H), 4.81 (d, *J* = 10.5 Hz, 2H), 4.23 (dd, *J* = 14.5, 10.5 Hz, 1H), 4.03--3.92 (m, 1H), 3.67--3.58 (m, 1H), 2.32 (t, *J* = 12.5 Hz, 1H), 2.24 (dd, *J* = 12.5, 5.5 Hz, 1H), 0.70 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.02 (C), 165.46 (C), 140.37 (C), 132.96 (C), 130.10 (two CH), 129.44 (C), 129.40 (CH), 128.58 (CH), 128.31 (two CH), 125.89 (CH), 123.12 (CH), 110.65 (CH), 103.65 (C), 75.67 (CH~2~), 63.74 (CH~2~), 61.01 (CH), 58.87 (C), 44.09 (CH), 39.39 (CH~2~), 13.11 (CH~3~); MS (*m*/*z*, relative intensity): 439 (M^+^, 42), 348 (26), 347 (100), 345 (19), 300 (32), 286 (39), 272 (61), 258 (30), 244 (19), 230 (17), 202 (10), 165 (17), 145 (35), 129 (47), 117 (35), 91 (19), 77 (14); exact mass calculated for C~22~H~21~N~3~O~7~ (M^+^): 439.1380; found: 439.1376.

### (1*S*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4a**) {#sec4.3.2}

White solid, mp: 187--188 °C; \[α\]~D~^26^ −7.8 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.66 (d, *J* = 7.5 Hz, 1H), 7.42--7.38 (m, 1H), 7.23--7.19 (m, 1H), 7.18--7.13 (m, 2H), 7.12--7.07 (m, 2H), 7.00--6.96 (m, 2H), 6.68 (d, *J* = 7.5 Hz, 1H), 5.10--4.98 (m, 3H), 4.13--4.06 (m, 1H), 3.94--3.86 (m, 1H), 3.74--3.65 (m, 1H), 2.54--2.47 (m, 1H), 2.19 (t, *J* = 13.0 Hz, 1H), 0.68 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.88 (C), 163.96 (C), 140.42 (C), 133.78 (C), 130.88 (C), 129.83 (two CH), 129.31 (CH), 128.48 (CH), 128.46 (two CH), 123.60 (CH), 123.41 (CH), 109.81 (CH), 104.49 (C), 75.70 (CH~2~), 63.20 (CH~2~), 62.46 (CH), 58.35 (C), 44.51 (CH), 38.07 (CH~2~), 13.12 (CH~3~).

For the same reaction with the *E*/*Z* mixture of **2a** (*E*/*Z* = 2.2:1): To a solution of catalyst **IV** (15.5 mg, 0.04 mmol, 0.2 equiv) and **1a** (40 mg, 0.18 mmol, 1 equiv) in CH~3~CN (0.4 mL) was added **2a** (*E*/*Z* = 2.2:1, 60.8 mg, 0.27 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 24 h until the completion of the reaction, as monitored by TLC. The resulting mixture was diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL), dried over MgSO~4~, and concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 78:22. The residue was purified by flash column chromatography with 20% EtOAc--hexane (*R*~*f*~ = 0.37 for **3a**, *R*~*f*~ = 0.50 for **4a** in 40% EtOAc--hexane) to give products **3a** and **4a** (53 mg, 66% yield). Chiral HPLC analysis for **3a**: Chiralpak IC (elute: 20% IPA--hexane), flow rate 1.0 mL/min, detector: 280 nm, *t*~1~ = 6.52 min, *t*~2~ = 7.47 min, 4:96 er. Chiral HPLC analysis for **4a**: Chiralpak IC (elute: 20% IPA--hexane), flow rate 1.0 mL/min, detector: 271 nm, *t*~1~ = 5.92 min, *t*~2~ = 12.3 min, 80.4:19.6 er.

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2′-oxo-2-(*p*-tolyl)spiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3b**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2′-oxo-2-(*p*-tolyl)spiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4b**) {#sec4.3.3}

38 mg, yield: (73%). Diastereomeric ratio, **3b**/**4b**: 84:16.

For **3b**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.47); mp 186--188 °C; \[α\]~D~^26^ 18.3 (*c* 1, CHCl~3~); IR (neat): 3395, 3205, 2957, 2925, 2854, 1749, 1709, 1557, 1466, 1259, 1085, 1021, 800 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.88--7.80 (m, 2H), 7.25--7.20 (m, 1H), 7.13 (t, *J* = 7.5 Hz, 1H), 6.81 (d, *J* = 7.5 Hz, 2H), 6.78--6.73 (m, 3H), 5.39 (s, 1H), 4.83--4.74 (m, 2H), 4.27--4.19 (m, 1H), 4.03--3.94 (m, 1H), 3.68--3.60 (m, 1H), 2.30 (t, *J* = 12.5 Hz, 1H), 2.23 (dd, *J* = 12.5, 5.5 Hz, 1H), 2.15 (s, 3H), 0.71 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.21 (C), 165.52 (C), 140.43 (C), 138.39 (C), 129.97 (two CH), 129.83 (C), 129.57 (C), 129.33 (CH), 128.96 (two CH), 125.88 (CH), 123.07 (CH), 110.67 (CH), 103.71 (C), 75.70 (CH~2~), 63.72 (CH~2~), 60.73 (CH), 58.89 (C), 44.02 (CH), 39.39 (CH~2~), 21.13 (CH~3~), 13.10 (CH~3~); MS (*m*/*z*, relative intensity): 453 (M^+^, 1), 361 (6), 286 (7), 184 (10), 143 (28), 133 (65), 104 (71), 91 (100), 77 (49); exact mass calculated for C~23~H~23~N~3~O~7~ (M^+^): 453.1536; found: 453.1533.

For **4b**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.55); yellow oil, \[α\]~D~^26^ −3.2 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.65 (d, *J* = 7.5 Hz, 1H), 7.20 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.14 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.07 (s, 1H), 6.91 (d, *J* = 8.0 Hz, 2H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.66 (d, *J* = 8.0 Hz, 1H), 5.07--4.97 (m, 3H), 4.09 (dd, *J* = 13.0, 10.5 Hz, 1H), 3.95--3.87 (m, 1H), 3.77--3.68 (m, 1H), 2.50 (dd, *J* = 13.0, 5.0 Hz, 1H), 2.20 (s, 3H), 2.22--2.14 (m, 1H), 0.71 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.69 (C), 163.98 (C), 140.36 (C), 138.27 (C), 131.04 (C), 130.72 (C), 129.72 (two CH), 129.21 (CH), 129.11 (two CH), 123.57 (CH), 123.47 (CH), 109.67 (CH), 104.59 (C), 75.74 (CH~2~), 63.17 (CH~2~), 62.17 (CH), 58.29 (C), 44.49 (CH), 38.06 (CH~2~), 21.20 (CH~3~), 13.14 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 1′-Methyl-3-nitro-4-(nitromethyl)-2′-oxo-2-(*p*-tolyl)spiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3c**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 1′-Methyl-3-nitro-4-(nitromethyl)-2′-oxo-2-(*p*-tolyl)spiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4c**) {#sec4.3.4}

34 mg, yield: (68%). Diastereomeric ratio, **3c**/**4c**: 90:10.

For **3c**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.57); yellow oil; \[α\]~D~^26^ 2.3 (*c* 1, CHCl~3~); IR (neat): 2962, 2928, 2855, 1742, 1714, 1612, 1559, 1378, 1256, 1096, 1013, 802, 755 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.85 (d, *J* = 7.5 Hz, 1H), 7.28 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.15 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.80 (d, *J* = 8.0 Hz, 2H), 6.74 (d, *J* = 8.0 Hz, 2H), 6.70 (d, *J* = 7.5 Hz, 1H), 5.42 (s, 1H), 4.82--4.75 (m, 2H), 4.26--4.20 (m, 1H), 4.02--3.95 (m, 1H), 3.67--3.60 (m, 1H), 3.04 (s, 3H), 2.31 (t, *J* = 13.0 Hz, 1H), 2.20--2.15 (m, 1H), 2.14 (s, 3H), 0.71 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.57 (C), 165.59 (C), 143.57 (C), 138.24 (C), 129.93 (two CH), 129.31 (C), 129.28 (CH), 128.89 (two CH), 125.49 (CH), 122.97 (CH), 110.23 (C), 108.89 (CH), 103.81 (C), 75.76 (CH~2~), 63.68 (CH~2~), 60.64 (CH), 58.53 (C), 44.04 (CH), 39.49 (CH~2~), 26.89 (CH~3~), 21.12 (CH~3~), 13.10 (CH~3~); MS (*m*/*z*, relative intensity): 467 (M^+^, 23), 375 (88), 328 (16), 314 (27), 300 (35), 286 (17), 160 (23), 159 (30), 143 (17), 130 (17), 101 (45), 59 (100); exact mass calculated for C~24~H~25~N~3~O~7~ (M^+^): 467.1693; found: 467.1690.

For **4c**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.67); yellow oil; \[α\]~D~^26^ −1.3 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.63 (d, *J* = 7.5 Hz, 1H), 7.27--7.21 (m, 1H), 7.15 (t, *J* = 7.5 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 2H), 6.83 (d, *J* = 8.0 Hz, 2H), 6.61 (d, *J* = 8.0 Hz, 1H), 5.19--5.10 (m, 1H), 5.01--4.96 (m, 2H), 4.09 (dd, *J* = 13.0, 10.5 Hz, 1H), 3.95--3.88 (m, 1H), 3.76--3.68 (m, 1H), 2.86 (s, 3H), 2.43 (dd, *J* = 13.0, 6.0 Hz, 1H), 2.22--2.14 (m, 1H), 2.19 (s, 3H), 0.71 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.17 (C), 164.00 (C), 143.56 (C), 138.12 (C), 130.66 (C), 130.36 (C), 129.65 (two CH), 129.20 (CH), 128.95 (two CH), 123.47 (CH), 122.89 (CH), 108.20 (CH), 104.56 (C), 75.79 (CH~2~), 63.13 (CH~2~), 62.17 (CH), 58.09 (C), 44.31 (CH), 37.78 (CH~2~), 26.16 (CH~3~), 21.17 (CH~3~), 13.14 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Bromophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3d**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Bromophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4d**) {#sec4.3.5}

39 mg, yield: (66%). Diastereomeric ratio, **3d**/**4d**: 83:17.

For **3d**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.50); white solid; mp 167--169 °C; \[α\]~D~^26^ 10.3 (*c* 1, CHCl~3~); IR (neat): 2962, 2926, 2855, 1751, 1708, 1620, 1557, 1489, 1473, 1344, 1261, 1082, 1017, 860, 802, 758 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.82 (d, *J* = 8.0 Hz, 1H), 7.56 (s, 1H), 7.27--7.22 (m, 1H), 7.19--7.10 (m, 3H), 6.79--6.74 (m, 3H), 5.38 (s, 1H), 4.84--4.74 (m, 2H), 4.28--4.20 (m, 1H), 4.08--3.98 (m, 1H), 3.73--3.64 (m, 1H), 2.36--2.21 (m, 2H), 0.78 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.60 (C), 165.33 (C), 140.33 (C), 131.92 (C), 131.72 (two CH), 131.50 (two CH), 129.66 (CH), 128.97 (C), 125.79 (CH), 123.28 (CH), 123.03 (C), 110.82 (CH), 103.3 (C), 75.52 (CH~2~), 63.97 (CH~2~), 60.35 (CH), 58.69 (C), 44.05 (CH), 39.38 (CH~2~), 13.21 (CH~3~); MS (*m*/*z*, relative intensity): 519 (M^+^ + 2, 4), 517 (M^+^, 4), 427 (47), 425 (55), 380 (12), 378 (12), 366 (13), 364 (13), 352 (23), 350 (22), 338 (11), 271 (19), 270 (16), 257 (10), 228 (10), 185 (12), 183 (12), 171 (16), 146 (62), 145 (90), 128 (100), 117 (83), 90 (30); exact mass calculated for C~22~H~20~BrN~3~O~7~ (M^+^): 517.0485; found: 517.0484.

For **4d**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.56); colorless oil; \[α\]~D~^26^ −55.1 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.64 (d, *J* = 7.5 Hz, 1H), 7.39 (s, 1H), 7.26--7.19 (m, 3H), 7.16 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.71 (d, *J* = 8.0 Hz, 1H), 5.05--4.96 (m, 3H), 4.09 (dd, *J* = 13.5, 11.0 Hz, 1H), 4.00--3.91 (m, 1H), 3.81--3.72 (m, 1H), 2.51 (dd, *J* = 13.5, 6.0 Hz, 1H), 2.19 (t, *J* = 13.5 Hz, 1H), 0.77 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.62 (C), 163.78 (C), 140.31 (C), 132.79 (C), 131.63 (two CH), 131.47 (two CH), 130.49 (C), 129.50 (CH), 123.77 (CH), 123.38 (CH), 122.90 (C), 109.96 (CH), 104.15 (C), 75.56 (CH~2~), 63.43 (CH~2~), 61.68 (CH), 58.25 (C), 44.46 (CH), 38.04 (CH~2~), 13.22 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3e**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4e**) {#sec4.3.6}

37 mg, yield: (65%). Diastereomeric ratio, **3e**/**4e**: 83:17.

For **3e**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.55); white solid; mp: 167--169 °C; \[α\]~D~^26^ 7.6 (*c* 1, CHCl~3~); IR (neat): 2962, 2854, 1746, 1712, 1612, 1559, 1469, 1375, 1350, 1261, 1011, 796, 756 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.84 (d, *J* = 7.5 Hz, 1H), 7.30 (dd, *J* = 7.5, 8.0 Hz, 1H), 7.18--7.12 (m, 3H), 6.77--6.71 (m, 3H), 5.41 (s, 1H), 4.83--4.73 (m, 2H), 4.28--4.20 (m, 1H), 4.07--3.99 (m, 1H), 3.72--3.64 (m, 1H), 3.06 (s, 3H), 2.31 (t, *J* = 13.0 Hz, 1H), 2.19 (dd, *J* = 12.5, 6.0 Hz, 1H), 0.78 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.20 (C), 165.39 (C), 143.56 (C), 132.05 (C), 131.69 (two CH), 131.45 (two CH), 129.63 (CH), 128.72 (C), 125.37 (CH), 123.18 (CH), 122.92 (C), 108.18 (CH), 103.40 (C), 75.57 (CH~2~), 63.94 (CH~2~), 60.25 (CH), 58.37 (C), 44.06 (CH), 39.48 (CH~2~), 26.95 (CH~3~), 13.21 (CH~3~); MS (*m*/*z*, relative intensity): 533 (M^+^ + 2, 43), 531 (M^+^, 43), 441 (39), 439 (46), 380 (39), 378 (39), 366 (41), 364 (37), 352 (21), 285 (20), 271 (21), 160 (83), 159 (100), 131 (35), 130 (54), 128 (44); exact mass calculated for C~23~H~22~BrN~3~O~7~ (M^+^): 531.0641; found: 531.0649.

For **4e**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.65); colorless oil; \[α\]~D~^26^ −4.8 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.62 (t, *J* = 7.5 Hz, 1H), 7.29--7.21 (m, 3H), 7.16 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.85 (d, *J* = 8.5 Hz, 2H), 6.65 (d, *J* = 8.0 Hz, 1H), 5.16--5.08 (m, 1H), 5.00 (s, 1H), 4.98 (dd, *J* = 13.0, 3.5 Hz, 1H), 4.09 (dd, *J* = 13.0, 10.5 Hz, 1H), 4.00--3.92 (m, 1H), 3.80--3.73 (m, 1H), 2.89 (s, 3H), 2.45 (dd, *J* = 13.0, 6.0 Hz, 1H), 2.20 (t, *J* = 13.0 Hz, 1H), 0.77 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.85 (C), 163.78 (C), 143.43 (C), 132.80 (C), 131.48 (four CH), 129.83 (C), 129.49 (CH), 123.68 (CH), 122.85 (CH), 122.78 (C), 108.43 (CH), 104.16 (C), 75.62 (CH~2~), 63.38 (CH~2~), 61.65 (CH), 58.02 (C), 44.29 (CH), 37.84 (CH~2~), 26.25 (CH~3~), 13.23 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Fluorophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3f**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Fluorophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4f**) {#sec4.3.7}

35 mg, yield: (67%). Diastereomeric ratio, **3f**/**4f**: 83:17.

For **3f**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.53); white solid; mp 186--187 °C; \[α\]~D~^26^ 29.9 (*c* 1, CHCl~3~); IR (neat): 3269, 2925, 2854, 1722, 1615, 1559, 1513, 1469, 1377, 1235, 755 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.99 (s, 1H), 7.83 (d, *J* = 7.5 Hz, 1H), 7.29--7.20 (m, 1H), 7.14 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.90--6.83 (m, 2H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.71 (t, *J* = 8.0 Hz, 2H), 5.41 (s, 1H), 4.79 (d, *J* = 10.5 Hz, 2H), 4.25 (t, *J* = 12.5 Hz, 1H), 4.07--3.97 (m, 1H), 3.72--3.62 (m, 1H), 2.34--2.20 (m, 2H), 0.77 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.08 (C), 165.41 (C), 162.84 (d, *J* = 247.3 Hz, C), 140.46 (C), 131.84 (d, *J* = 8 Hz, two CH), 129.60 (CH), 129.14 (C), 128.76 (d, *J* = 3.4 Hz, C), 125.77 (CH), 123.24 (CH), 115.31 (d, *J* = 21 Hz, two CH), 110.86 (CH), 103.46 (C), 75.54 (CH~2~), 63.88 (CH~2~), 60.17 (CH), 58.87 (C), 44.04 (CH), 39.28 (CH~2~), 13.24 (CH~3~); MS (*m*/*z*, relative intensity): 457 (M^+^, 17), 404 (11), 366 (24), 365 (100), 318 (13), 304 (13), 290 (25), 276 (12), 221 (10), 183 (11), 147 (22), 146 (23), 145 (22), 125 (17), 105 (31), 97 (35); exact mass calculated for C~22~H~20~FN~3~O~7~ (M^+^): 457.1285; found: 457.1277.

For **4f**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.56); colorless oil; \[α\]~D~^26^ −0.7 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.65 (d, *J* = 7.5 Hz, 1H), 7.26--7.19 (m, 2H), 7.18--7.13 (m, 1H), 7.02--6.96 (m, 2H), 6.81 (dd, *J* = 8.5, 8.5 Hz, 2H), 6.69 (d, *J* = 8.0 Hz, 1H), 5.07--4.97 (m, 3H), 4.09 (dd, *J* = 13.5, 10.5 Hz, 1H), 3.99--3.90 (m, 1H), 3.79--3.71 (m, 1H), 2.51 (dd, *J* = 13.5, 5.5 Hz, 1H), 2.18 (t, *J* = 13.5 Hz, 1H), 0.76 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.60 (C), 163.87 (C), 162.85 (d, *J* = 248 Hz, C), 140.29 (C), 131.67 (d, *J* = 8 Hz, two CH), 130.64 (C), 129.66 (d, *J* = 3.5 Hz, C), 129.43 (CH), 123.74 (CH), 123.41 (CH), 115.44 (d, *J* = 21 Hz, two CH), 109.83 (CH), 104.36 (C), 75.61 (CH~2~), 63.34 (CH~2~), 61.56 (CH), 58.32 (C), 44.42 (CH), 38.00 (CH~2~), 13.26 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Fluorophenyl)-1′-methyl-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3g**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Fluorophenyl)-1′-methyl-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4g**) {#sec4.3.8}

33 mg, yield: (65%). Diastereomeric ratio, **3g**/**4g**: 78:22.

For **3g**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.55); white solid; mp 168--169 °C; \[α\]~D~^26^ 69.0 (*c* 1, CHCl~3~); IR (neat): 3017, 2926, 2885, 1695, 1613, 1596, 1548, 1472, 1375, 1351, 1279, 756 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.85 (d, *J* = 7.0 Hz, 1H), 7.30 (d, *J* = 7.5 Hz, 1H), 7.16 (d, *J* = 7.5 Hz, 1H), 6.87--6.83 (m, 2H), 6.73--6.67 (m, 3H), 5.44 (s, 1H), 4.83--4.75 (m, 2H), 4.28--4.21 (m, 1H), 4.06--3.99 (m, 1H), 3.70--3.63 (m, 1H), 3.05 (s, 3H), 2.31 (t, *J* = 12.5 Hz, 1H), 2.19 (dd, *J* = 12.5, 6.0 Hz, 1H), 0.78 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.32 (C), 165.49 (C), 162.80 (d, *J* = 247 Hz, C), 143.57 (C), 131.79 (d, *J* = 8 Hz, two CH), 129.56 (CH), 128.86 (C), 128.84 (d, *J* = 3 Hz, C), 125.39 (CH), 123.14 (CH), 115.24 (d, *J* = 21 Hz, two CH), 109.07 (CH), 103.52 (C), 75.63 (CH~2~), 63.84 (CH~2~), 60.16 (CH), 58.49 (C), 44.05 (CH), 39.33 (CH~2~), 26.91 (CH~3~), 13.25 (CH~3~); MS (*m*/*z*, relative intensity): 471 (M^+^, 92), 379 (100), 332 (24), 318 (56), 305 (33), 304 (85), 290 (33), 276 (11), 262 (11), 160 (38), 159 (91), 147 (30), 130 (26); exact mass calculated for C~23~H~22~FN~3~O~7~ (M^+^): 471.1442; found: 471.1440.

For **4g**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.63); white solid; mp 143--144 °C; \[α\]~D~^26^ −19.8 (*c* 0.4, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.63 (d, *J* = 7.0 Hz, 1H), 7.28--7.24 (m, 1H), 7.18--7.14 (m, 1H), 6.97--6.93 (m, 2H), 6.80 (t, *J* = 8.5 Hz, 2H), 6.64 (d, *J* = 7.5 Hz, 1H), 5.17--5.09 (m, 1H), 5.04 (s, 1H), 4.98 (d, *J* = 13.0, 3.5 Hz, 1H), 4.09 (dd, *J* = 13.0, 10.0 Hz, 1H), 3.95 (dq, *J* = 10.7, 7.1 Hz, 1H), 3.75 (dq, *J* = 10.7, 7.2 Hz, 1H), 2.87 (s, 3H), 2.45 (dd, *J* = 13.0, 6.0 Hz, 1H), 2.20 (t, *J* = 7.0 Hz, 1H), 0.77 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.97 (C), 163.88 (C), 162.78 (d, *J* = 247 Hz, C), 143.46 (C), 131.60 (d, *J* = 8 Hz, two CH), 130.00 (C), 129.63 (d, *J* = 3 Hz, C), 129.42 (CH), 123.65 (CH), 122.87 (CH), 115.26 (d, *J* = 21 Hz, two CH), 108.34 (CH), 104.33 (C), 75.66 (CH~2~), 63.30 (CH~2~), 61.57 (CH), 58.13 (C), 44.31 (CH), 37.69 (CH~2~), 26.18 (CH~3~), 13.27 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2-(4-nitrophenyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3h**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 3-Nitro-4-(nitromethyl)-2-(4-nitrophenyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4h**) {#sec4.3.9}

39 mg, yield: (70%). Diastereomeric ratio, **3h**/**4h**: 70:30.

For **3h**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.45); white solid; mp 191--193 °C; \[α\]~D~^26^ 1.4 (*c* 1, CHCl~3~); IR (neat): 2976, 2885, 1718, 1559, 1515, 1474, 1371, 1252, 792, 749 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.90 (d, *J* = 8.5 Hz, 2H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.53 (s, 1H), 7.29--7.22 (m, 1H), 7.17 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.10 (d, *J* = 8.5 Hz, 2H), 6.76 (d, *J* = 7.5 Hz, 1H), 5.52 (s, 1H), 4.86--4.77 (m, 2H), 4.33--4.25 (m, 1H), 4.13--4.04 (m, 1H), 3.73--3.65 (m, 1H), 2.41--2.28 (m, 2H), 0.79 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.16 (C), 165.10 (C), 147.99 (C), 140.22 (C), 140.13 (C), 131.12 (two CH), 130.02 (CH), 128.43 (C), 125.74 (CH), 123.53 (CH), 123.29 (two CH), 110.98 (CH), 103.00 (C), 75.32 (CH~2~), 64.16 (CH~2~), 60.31 (CH), 58.79 (C), 44.26 (CH), 39.46 (CH~2~), 13.31 (CH~3~); MS (*m*/*z*, relative intensity): 485 (M^+^ + 1, 24), 484 (M^+^, 100), 437 (9), 392 (81), 345 (89), 331 (33), 317 (94), 305 (23), 271 (37), 228 (15), 202 (10), 145 (39), 117 (25); exact mass calculated for C~22~H~20~N~4~O~9~ (M^+^): 484.1230; found: 484.1233.

For **4h**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.55); white solid; mp 168--169 °C; \[α\]~D~^26^ −70.5 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.99 (d, *J* = 8.5 Hz, 2H), 7.68 (d, *J* = 7.5 Hz, 1H), 7.29--7.14 (m, 5H), 6.71 (d, *J* = 7.5 Hz, 1H), 5.17 (s, 1H), 5.08--4.98 (m, 2H), 4.16--4.07 (m, 1H), 4.06--3.95 (m, 1H), 3.82--3.71 (m, 1H), 2.56 (dd, *J* = 13.2, 5.7 Hz, 1H), 2.25 (t, *J* = 13.2 Hz, 1H), 0.78 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.05 (C), 163.56 (C), 147.97 (C), 140.93 (C), 140.09 (C), 130.82 (two CH), 129.90 (C), 129.84 (CH), 124.05 (CH), 123.49 (two CH), 123.45 (CH), 110.07 (CH), 103.80 (C), 75.42 (CH~2~), 63.65 (CH~2~), 61.58 (CH), 58.39 (C), 44.49 (CH), 38.25 (CH~2~), 13.31 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Ethylphenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3i**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(4-Ethylphenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4i**) {#sec4.3.10}

39 mg, yield: (73%). Diastereomeric ratio, **3i**/**4i**: 82:18.

For **3i**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.58); white solid; mp 193--195 °C; \[α\]~D~^26^ 10.1 (*c* 1, CHCl~3~); IR (neat): 2957, 2888, 1719, 1447, 1188, 1064, 960, 795, 748 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.85 (d, *J* = 7.5 Hz, 1H), 7.52 (s, 1H), 7.26--7.20 (m, 1H), 7.14 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.85 (d, *J* = 8.0 Hz, 2H), 6.79 (d, *J* = 8.0 Hz, 2H), 6.75 (d, *J* = 8.0 Hz, 1H), 5.41 (s, 1H), 4.84--4.75 (m, 2H), 4.26--4.19 (m, 1H), 3.99--3.92 (m, 1H), 3.67--3.60 (m, 1H), 2.45 (q, *J* = 7.5 Hz, 2H), 2.31 (t, *J* = 12.5 Hz, 1H), 2.25--2.20 (m, 1H), 1.06 (t, *J* = 7.5 Hz, 3H), 0.68 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.93 (C), 165.52 (C), 144.75 (C), 140.34 (C), 130.10 (C), 130.05 (two CH), 129.58 (C), 129.33 (CH), 127.79 (two CH), 125.93 (CH), 123.09 (CH), 110.58 (CH), 103.75 (C), 75.71 (CH~2~), 63.69 (CH~2~), 60.72 (CH), 58.79 (C), 43.96 (CH), 39.49 (CH~2~), 28.53 (CH~2~), 15.56 (CH~3~), 13.07 (CH~3~); MS (*m*/*z*, relative intensity): 467 (M^+^, 18), 439 (9), 375 (45), 374 (21), 373 (51), 329 (26), 328 (100), 300 (48), 272 (11), 257 (10), 183 (25), 171 (26), 145 (24), 129 (34), 117 (25), 71 (26); exact mass calculated for C~24~H~25~N~3~O~7~ (M^+^): 467.1693; found: 467.1696.

For **4i**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.65); white solid; mp 185--187 °C; \[α\]~D~^26^ −25 (*c* 1, CHCl~3~); IR (neat): 3450, 3019, 2964, 2906, 1470, 1454, 1413, 1262, 1217, 1096, 1017 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.66 (d, *J* = 7.5 Hz, 1H), 7.20 (td, *J* = 7.5, 1.0 Hz, 1H), 7.14 (td, *J* = 7.5, 1.0 Hz, 1H), 7.09 (brs, 1H), 6.94 (d, *J* = 8.5 Hz, 2H), 6.90 (d, *J* = 8.5 Hz, 2H), 6.67 (d, *J* = 7.5 Hz, 1H), 5.07--4.99 (m, 3H), 4.12--4.05 (m, 1H), 3.91--3.84 (m, 1H), 3.76--3.69 (m, 1H), 2.53--2.47 (m, 3H), 2.18 (t, *J* = 13.0 Hz, 1H), 1.10 (t, *J* = 7.5 Hz, 3H), 0.66 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.70 (C), 163.97 (C), 144.63 (C), 140.36 (C), 131.07 (C), 130.95 (C), 129.85 (two CH), 129.20 (CH), 127.92 (two CH), 123.57 (CH), 123.46 (CH), 109.68 (CH), 104.65 (C), 75.73 (CH~2~), 63.13 (CH~2~), 62.18 (CH), 58.26 (C), 44.47 (CH), 38.12 (CH~2~), 28.58 (CH~2~), 15.58 (CH~3~), 13.09 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 1′-Methyl-3-nitro-4-(nitromethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3j**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 1′-Methyl-3-nitro-4-(nitromethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4j**) {#sec4.3.11}

32 mg, yield: (66%). Diastereomeric ratio, **3j**/**4j**: 84:16.

For **3j**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.55); pale yellow oil; \[α\]~D~^26^ 57.2 (*c* 1, CHCl~3~); IR (neat): 2922, 2855, 1746, 1711, 1612, 1554, 1470, 1375, 1265, 853, 753 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.85 (d, *J* = 7.5 Hz, 1H), 7.30--7.25 (m, 1H), 7.15 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.11--7.06 (m, 1H), 7.00 (t, *J* = 7.5 Hz, 2H), 6.87 (d, *J* = 7.5 Hz, 2H), 6.69 (d, *J* = 7.5 Hz, 1H), 5.46 (s, 1H), 4.85--4.76 (m, 2H), 4.27--4.20 (m, 1H), 4.02--3.94 (m, 1H), 3.66--3.58 (m, 1H), 3.04 (s, 3H), 2.33 (t, *J* = 12.5 Hz, 1H), 2.23--2.16 (m, 1H), 0.70 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.48 (C), 165.52 (C), 143.54 (C), 133.06 (C), 130.05 (two CH), 129.18 (C), 129.36 (CH), 128.46 (CH), 128.23 (two CH), 125.47 (CH), 123.02 (CH), 108.92 (CH), 103.73 (C), 75.72 (CH~2~), 63.71 (CH~2~), 60.96 (CH), 58.54 (C), 44.12 (CH), 39.45 (CH~2~), 26.88 (CH~3~), 13.12 (CH~3~); MS (*m*/*z*, relative intensity): 454 (M^+^ + 1, 13), 453 (M^+^, 55), 361 (26), 314 (11), 300 (25), 286 (28), 272 (12), 204 (25), 203 (74), 188 (100), 160 (69), 159 (48), 147 (20), 146 (51), 130 (19), 75 (19); exact mass calculated for C~23~H~23~N~3~O~7~ (M^+^): 453.1536; found: 453.1538.

For **4j**: Column chromatography eluents: 40% EtOAc--hexane (TLC: *R*~*f*~ = 0.62); pale yellow oil; pale yellow oil; \[α\]~D~^26^ −11.9 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.65 (d, *J* = 7.5 Hz, 1H), 7.28--7.21 (m, 1H), 7.19--7.05 (m, 4H), 6.94 (d, *J* = 8.0 Hz, 2H), 6.61 (d, *J* = 8.0 Hz, 1H), 5.20--5.10 (m, 1H), 5.03 (s, 1H), 5.00 (dd, *J* = 13.0, 3.5 Hz, 1H), 4.10 (dd, *J* = 13.0, 10.5 Hz, 1H), 3.95--3.87 (m, 1H), 3.74--3.96 (m, 1H), 2.85 (s, 3H), 2.45 (dd, *J* = 13.0, 5.5 Hz, 1H), 2.21 (t, *J* = 13.0 Hz, 1H), 0.69 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.07 (C), 163.97 (C), 143.52 (C), 133.74 (C), 130.22 (C), 129.74 (two CH), 129.27 (CH), 128.38 (CH), 128.29 (two CH), 123.51 (CH), 122.89 (CH), 108.21 (CH), 104.43 (C), 75.74 (CH~2~), 63.16 (CH~2~), 62.51 (CH), 58.15 (C), 44.41 (CH), 37.69 (CH~2~), 26.10 (CH~3~), 13.13 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 2-(3-Bromophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**3k**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 2-(3-Bromophenyl)-3-nitro-4-(nitromethyl)-2′-oxospiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**4k**) {#sec4.3.12}

24 mg, yield: (40%). Diastereomeric ratio, **3k**/**4k**: 71:29.

For **3k**: Column chromatography eluents: 30% EtOAc--hexane (TLC: *R*~*f*~ = 0.54); white solid; mp 125--126 °C; \[α\]~D~^26^ −17.5 (*c* 1, CHCl~3~); IR (neat): 2964, 2928, 2855, 1715, 1619, 1595, 1557, 1472, 1261, 1081, 1021, 799, 755, 694 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.82 (d, *J* = 7.5 Hz, 1H), 7.59 (s, 1H), 7.28--7.23 (m, 2H), 7.16 (dd, *J* = 7.5, 7.5 Hz, 1H), 7.01 (s, 1H), 6.91 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 6.77 (d, *J* = 7.5 Hz, 1H), 5.36 (s, 1H), 4.83--4.76 (m, 2H), 4.28--4.22 (m, 1H), 4.07--4.02 (m, 1H), 3.78--3.70 (m, 1H), 2.36--2.24 (m, 2H), 0.79 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.59 (C), 165.27 (C), 140.29 (C), 135.10 (C), 133.06 (CH), 131.72 (CH), 129.80 (CH), 129.71 (CH), 128.88 (C), 128.79 (CH), 125.81 (CH), 123.28 (CH), 122.26 (C), 110.81 (CH), 103.31 (C), 75.52 (CH~2~), 64.01 (CH~2~), 60.39 (CH), 58.73 (C), 44.08 (CH), 39.29 (CH~2~), 13.24 (CH~3~); MS (*m*/*z*, relative intensity): 519 (M^+^ + 2, 44), 517 (M^+^, 45) 427 (25), 425 (45), 423 (22), 381 (31), 380 (100), 379 (33), 378 (94), 354 (23), 353 (24), 352 (66), 350 (47), 185 (38), 183 (41), 146 (99), 145 (75), 101 (61); exact mass calculated for C~22~H~20~BrN~3~O~7~ (M^+^): 517.0485; found: 517.0486.

For **4k**: Column chromatography eluents: 30% EtOAc--hexane (TLC: *R*~*f*~ = 0.66); pale yellow solid, mp: 164--165 °C; \[α\]~D~^26^ −48.9 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.68--7.61 (m, 2H), 7.31 (d, *J* = 7.5 Hz, 1H), 7.26--7.21 (m, 1H), 7.19--7.12 (m, 2H), 7.02--6.94 (m, 2H), 6.74 (d, *J* = 7.5 Hz, 1H), 5.06--4.97 (m, 3H), 4.13--4.05 (m, 1H), 3.99--3.90 (m, 1H), 3.83--3.75 (m, 1H), 2.52 (dd, *J* = 13.0, 5.5 Hz, 1H), 2.19 (t, *J* = 13.0 Hz, 1H), 0.76 (t, *J* = 7.5 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 178.73 (C), 163.72 (C), 140.37 (C), 135.97 (C), 132.85 (CH), 131.68 (CH), 130.36 (C), 129.98 (CH), 129.55 (CH), 128.49 (CH), 123.79 (CH), 123.29 (CH), 122.35 (C), 110.12 (CH), 104.22 (C), 75.56 (CH~2~), 63.47 (CH~2~), 61.61 (CH), 58.31 (C), 44.36 (CH), 38.17 (CH~2~), 13.25 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-Ethyl 3-Amino-4-(aminomethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**5a**) and (1*S*,2*S*,3*R*,4*R*)-Ethyl 3-Amino-4-(aminomethyl)-2′-oxo-2-phenylspiro\[cyclopentane-1,3′-indoline\]-3-carboxylate (**6a**) {#sec4.3.13}

To a solution of catalyst **IV** (9.7 mg, 0.02 mmol, 0.2 equiv) and **1a** (25 mg, 0.11 mmol, 1 equiv) in CH~3~CN (0.4 mL) was added (*Z*)-**2a** (38 mg, 0.17 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 24 h until the completion of the reaction, as monitored by TLC. The resulting solution was concentrated in vacuo to give a residue. To the solution of the above residue in MeOH (1 mL) was added Pd/C (13 mg, 10% palladium on carbon), and the suspension was stirred under a balloon of hydrogen at room temperature for 18 h. The reaction mixture was filtered through celite and washed with EtOAc, and the filtrate was concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 88:12. The residue was purified by flash column chromatography with 25% EtOAc--hexane (*R*~*f*~ = 0.31 for **5a**, *R*~*f*~ = 0.44 for **6a** in 60% EtOAc--hexane) to give products **5a** and **6a** (21 mg, 48% yield).

Selected data for **5a**: white solid; mp: 153--155 °C; \[α\]~D~^26^ 2.3 (*c* 1, CHCl~3~); IR (neat): 3263, 2928, 1722, 1617, 1554, 1515, 1469, 1234, 1021, 753 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 8.12 (d, *J* = 8.0 Hz, 1H), 7.28--7.21 (m, 1H), 7.19--7.09 (m, 3H), 7.04 (d, *J* = 7.5, 7.5 Hz, 2H), 6.83 (d, *J* = 7.5 Hz, 2H), 6.65 (d, *J* = 8.0 Hz, 1H), 6.05 (brs, NH~2~), 5.67 (brs, NH~2~), 5.07 (dd, *J* = 14.0, 7.5 Hz, 1H), 4.61 (dd, *J* = 14.0, 7.5 Hz, 1H), 4.30--4.18 (m, 3H), 3.92--3.82 (m, 1H), 2.73 (dd, *J* = 14.0, 9.0 Hz, 1H), 2.28 (dd, *J* = 13.0, 11.0 Hz, 1H), 1.27 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 182.14 (C), 172.75 (C), 140.68 (C), 132.82 (C), 132.06 (C), 130.37 (two CH), 128.80 (CH), 128.74 (two CH), 128.69 (CH), 128.11 (CH), 122.88 (CH), 109.85 (CH), 76.56 (C), 76.26 (CH~2~), 63.77 (CH), 62.72 (CH~2~), 57.14 (C), 44.11 (CH), 40.09 (CH~2~), 14.43 (CH~3~); MS (*m*/*z*, relative intensity): 379 (M^+^, 20), 361 (14), 287 (30), 257 (12), 222 (19), 183 (37), 146 (24), 125 (22), 111 (41), 97 (61), 83 (57), 71 (68), 57 (100); exact mass calculated for C~22~H~25~N~3~O~3~ (M^+^): 379.1896; found: 379.1897.

Selected data for **6a**: colorless oil; \[α\]~D~^26^ −2.1 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.51 (s, 1H), 7.39--7.36 (m, 1H), 7.29--7.20 (m, 5H), 7.17 (dd, *J* = 7.5 Hz, 1H), 6.79 (d, *J* = 7.5 Hz, 1H), 4.86--4.76 (m, 2H), 4.37 (d, *J* = 13.5 Hz, 1H), 4.08 (s, 1H), 4.04--3.96 (m, 1H), 3.93--3.85 (m, 1H), 2.69 (dd, *J* = 13.0, 7.0 Hz, 1H), 2.13--2.07 (m, 1H), 0.87 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 179.62 (C), 167.94 (C), 140.46 (C), 134.90 (C), 129.92 (C), 129.42 (two CH), 128.93 (CH), 128.30 (two CH), 127.87 (CH), 123.21 (CH), 122.69 (CH), 109.74 (CH), 91.55 (C), 74.67 (CH~2~), 64.62 (CH), 62.20 (CH~2~), 59.79 (C), 41.31 (CH and CH~2~), 13.44 (CH~3~).

### (1*R*,2*S*,3*R*,4*R*)-1′-Methyl-3-nitro-4-(nitromethyl)-2-phenylspiro\[cyclopentane-1,3′-indolin\]-2′-one (**7a**) and (1*S*,2*S*,3*R*,4*R*)-1′-Methyl-3-nitro-4-(nitromethyl)-2-phenylspiro\[cyclopentane-1,3′-indolin\]-2′-one (**8a**) {#sec4.3.14}

To a solution of catalyst **IV** (10.9 mg, 0.03 mmol, 0.2 equiv) and **1b** (30 mg, 0.13 mmol, 1 equiv) in CH~2~Cl~2~ (0.4 mL) was added nitrostyrene (29 mg, 0.19 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 46 h until the completion of the reaction, as monitored by TLC. The resulting mixture was diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL), dried over MgSO~4~, and concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 81:19. The residue was purified by flash column chromatography with 10% EtOAc--hexane (*R*~*f*~ = 0.51 for **8a**, *R*~*f*~ = 0.42 for **7a** in 40% EtOAc--hexane) to give products **7a** (**7a**) and **8a** (**8a**) (22 mg, 45% yield).

Selected data for **7a**: white solid; 178 °C (decomposed); \[α\]~D~^26^ 5.6 (*c* 1, CHCl~3~); IR (neat): 2920, 2851, 1708, 1612, 1554, 1494, 1470, 1377, 1355, 752, 698 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 7.25--7.16 (m, 2H), 7.09--6.99 (m, 4H), 6.90--6.85 (m, 2H), 6.62 (d, *J* = 7.5 Hz, 1H), 5.89 (dd, *J* = 11.0, 10.0 Hz, 1H), 4.78--4.67 (m, 2H), 4.53 (d, *J* = 11.5 Hz, 1H), 4.00--3.90 (m, 1H), 3.06 (s, 3H), 2.54 (dd, *J* = 13.5, 10.0 Hz, 1H), 2.29 (dd, *J* = 13.5, 7.5 Hz, 1H); ^13^C NMR (125 MHz, CDCl~3~): δ 176.57 (C), 143.34 (C), 132.54 (C), 129.29 (CH), 129.25 (C), 128.58 (two CH), 128.44 (CH), 127.49 (two CH), 123.87 (CH), 122.85 (CH), 108.91 (CH), 89.20 (CH), 75.23 (CH~2~), 58.40 (CH), 57.79 (C), 39.10 (CH~2~), 37.88 (CH), 26.75 (CH~3~); MS (*m*/*z*, relative intensity): 382 (M^+^ + 1, 20), 381 (M^+^, 83), 335 (8), 288 (23), 274 (45), 160 (73), 130 (100), 129 (56), 115 (20), 91 (18); exact mass calculated for C~20~H~19~N~3~O~5~ (M^+^): 381.1325; found: 381.1323.

Selected data for **8a**: white solid; 191 °C (decomposed); \[α\]~D~^26^ −14.9 (*c* 1, CHCl~3~); ^1^H NMR (500 MHz, CDCl~3~): δ 7.45 (d, *J* = 7.0 Hz, 1H), 7.28--7.23 (m, 2H), 7.18--7.07 (m, 4H), 6.93 (d, *J* = 7.0 Hz, 2H), 6.61 (d, *J* = 8.0 Hz, 1H), 6.10 (t, *J* = 9.5 Hz, 1H), 4.63 (dd, *J* = 14.0, 7.0 Hz, 1H), 4.53 (dd, *J* = 14.0, 8.0 Hz, 1H), 4.44--4.33 (m, 1H), 4.29 (d, *J* = 9.0 Hz, 1H), 2.87 (s, 3H), 2.47--2.35 (m, 2H); ^13^C NMR (125 MHz, CDCl~3~): δ 177.31 (C), 143.79 (C), 132.97 (C), 129.41 (CH), 128.65 (two CH), 128.57 (CH), 128.42 (C), 127.81 (two CH), 123.42 (CH), 122.49 (CH), 108.56 (CH), 90.21 (CH), 75.47 (CH~2~), 59.67 (CH), 58.64 (C), 39.09 (CH~2~), 37.48 (CH), 26.06 (CH~3~).

### (1*R*,2*S*,3*S*,4*R*)-2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)spiro\[cyclopentane-1,3′-indolin\]-2′-one (**9b**) and (1*S*,2*S*,3*R*,4*R*)-2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)spiro\[cyclopentane-1,3′-indolin\]-2′-one (**8b**) {#sec4.3.15}

To a solution of catalyst **IV** (10.9 mg, 0.02 mmol, 0.2 equiv) and **1b** (30 mg, 0.13 mmol, 1 equiv) in CH~2~Cl~2~ (0.44 mL) was added (*E*)-1-bromo-4-(2-nitrovinyl)benzene (44.2 mg, 0.19 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 48 h until the completion of the reaction, as monitored by TLC. The resulting mixture was diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL), dried over Na~2~SO~4~, and concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 72:28. The residue was purified by flash column chromatography with 10% EtOAc--hexane (*R*~*f*~ = 0.38 for **9b**, *R*~*f*~ = 0.52 for **8b**, after developing twice in 20% EtOAc--hexane) to give products **9b** and **8b** (29 mg, 49% yield). Chiral HPLC analysis for **9b**: Chiralpak IA (elute: 20% IPA--hexane), flow rate 1.0 mL/min, detector: 254 nm, *t*~1~ = 9.57 min, *t*~2~ = 10.74 min, 11:89 er. Chiral HPLC analysis for **8b**: Chiralpak IC (elute: 30% IPA--hexane), flow rate 1.0 mL/min, detector: 215 nm, *t*~1~ = 7.45 min, *t*~2~ = 8.62 min, 61:39 er. Selected data for **9b**: pale yellow solid; mp 70--72 °C; \[α\]~D~^26^ 55.2 (*c* 1, CHCl~3~), 78% ee; IR (neat): 2988, 2879, 1743, 1712, 1558, 1375, 1347, 1242, 755, 701 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 7.27--7.21 (m, 2H), 7.17 (d, *J* = 8.4 Hz, 2H), 7.07 (dd, *J* = 7.5, 7.5 Hz, 1H), 6.76 (d, *J* = 8.4 Hz, 2H), 6.68 (d, *J* = 7.5 Hz, 1H), 5.82 (dd, *J* = 10.0, 11.0 Hz, 1H), 4.74 (dd, *J* = 14.5, 7.5 Hz, 1H), 4.67 (dd, *J* = 14.5, 7.5 Hz, 1H), 4.47 (d, *J* = 11.5 Hz, 1H), 4.00--3.89 (m, 1H), 3.08 (s, 3H), 2.52 (dd, *J* = 13.5, 10.0 Hz, 1H), 2.29 (dd, *J* = 13.5, 7.5 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 176.23 (C), 143.33 (C), 131.83 (two CH), 131.62 (C), 129.60 (CH), 129.24 (two CH), 128.81 (C), 123.75 (CH), 123.02 (CH), 122.71 (C), 109.23 (CH), 89.20 (CH), 75.11 (CH~2~), 57.89 (CH), 57.65 (C), 39.15 (CH~2~), 37.73 (CH), 26.82 (CH~3~); MS (*m*/*z*, relative intensity): 461 (M^+^ + 2, 31), 459 (M^+^, 31), 415 (11), 413 (11), 368 (19), 366 (21), 354 (40), 352 (40), 210 (41), 208 (39), 183 (20), 160 (100), 159 (51), 130 (56), 129 (82), 128 (53), 57 (36); exact mass calculated for C~20~H~18~BrN~3~O~5~ (M^+^): 459.0430; found: 459.0434.

Selected data for **8b**: yellow solid, mp: 160--161 °C; \[α\]~D~^26^ −9.8 (*c* 1, CHCl~3~), 22% ee; ^1^H NMR (400 MHz, CDCl~3~): δ 7.43 (dd, *J* = 7.5, 0.5 Hz, 1H), 7.30--7.20 (m, 3H), 7.15 (ddd, *J* = 7.5, 7.5, 0.5 Hz, 1H), 6.85--6.80 (m, 1H), 6.82 (d, *J* = 8.5 Hz, 1H), 6.65 (d, *J* = 7.5 Hz, 1H), 6.04 (dd, *J* = 9.5 Hz, 1H), 4.63 (dd, *J* = 14.0, 7.0 Hz, 1H), 4.53 (dd, *J* = 14.0, 8.0 Hz, 1H), 4.42--4.30 (m, 1H), 4.24 (d, *J* = 9.2 Hz, 1H), 2.91 (s, 3H), 2.44 (dd, *J* = 13.3, 7.3 Hz, 1H), 2.36 (dd, *J* = 13.3, 11.0 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 177.11 (C), 143.71 (C), 132.09 (C), 131.89 (two CH), 129.61 (CH), 129.55 (two CH), 127.99 (C), 123.56 (CH), 122.84 (C), 122.42 (CH), 108.80 (CH), 90.05 (CH), 75.32 (CH~2~), 58.93 (CH), 58.48 (C), 39.14 (CH~2~), 37.31 (CH), 26.18 (CH~3~).

### (1*S*,2*R*,3*R*,4*S*)-2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)spiro\[cyclopentane-1,3′-indolin\]-2′-one (ent-**9b**) and (1*R*,2*R*,3*S*,4*S*)-2-(4-Bromophenyl)-1′-methyl-3-nitro-4-(nitromethyl)spiro\[cyclopentane-1,3′-indolin\]-2′-one (ent-**8b**) {#sec4.3.16}

To a solution of catalyst **III** (16.3 mg, 0.03 mmol, 0.2 equiv) and **1b** (30 mg, 0.13 mmol, 1 equiv) in CH~2~Cl~2~ (0.44 mL) was added (*E*)-1-bromo-4-(2-nitrovinyl)benzene (44.2 mg, 0.19 mmol, 1.5 equiv). The resulting solution was stirred at 30 °C for 40 h until the completion of the reaction, as monitored by TLC. The resulting mixture was diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL), dried over Na~2~SO~4~, and concentrated in vacuo to give the crude residue. The diastereomeric ratio, as determined by ^1^H NMR analysis of the crude mixture, was found to be 64:36. The residue was purified by flash column chromatography with 10% EtOAc--hexane (*R*~*f*~ = 0.38 for **9b**, *R*~*f*~ = 0.52 for **8b**, after developing twice in 20% EtOAc--hexane) to give products **9b** and **8b** (31 mg, 52% yield). Chiral HPLC analysis for **9b**: Chiralpak IA (elute: 20% IPA--hexane), flow rate 1.0 mL/min, detector: 215 nm, *t*~1~ = 9.34 min, *t*~2~ = 10.53 min, 95:5 er. Chiral HPLC analysis for **8b**: Chiralpak IC (elute: 30% IPA--hexane), flow rate 1.0 mL/min, detector: 215 nm, *t*~1~ = 7.57 min, *t*~2~ = 8.80 min, 42.7:57.3 er.
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